SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) today announced that nearly 30 combination studies including IMiD® compounds, REVLIMID® (lenalidomide) and POMALYST®/IMNOVID® (pomalidomide), across a range of patient segments within multiple myeloma are being presented at the 57th American Society of Hematology Annual Meeting (ASH).
